| Gene symbol | CD7 | Synonyms | GP40, LEU-9, TP41, Tp40 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.3 | dbXrefs | |
| Description | CD7 molecule | ||||
| GTO ID | GTC3465 |
| Trial ID | NCT05885464 |
| Disease | Lymphoblastic Lymphoma | T-Cell Lymphoblastic Leukemia/Lymphoma | Lymphoblastic Leukemia |
| Altered gene | CD7 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BEAM-201 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
| Year | 2023 |
| Country | United States |
| Company sponsor | Beam Therapeutics Inc. |
| Other ID(s) | BTX-ALO-001 |
| Cohort 1 | |||||||||||
|
|||||||||||